ViroPharma Incorporated (VPHM) - Financial and Strategic SWOT Analysis Review

Summary

ViroPharma Incorporated (ViroPharma) is a biopharmaceutical company. It develops and commercializes products for the treatment of various serious life threatening ailments. The company’s marketed products include Cinryze, for the treatment of Hereditary Angioedema (HAE); Vancocin, for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus; Buccolam, for the treatment of Pediatric Epilepsy; and Plenadren for treatment of adrenal insufficiency in adults. The product pipeline of Viropharma comprises Cinryze (C1 esterase inhibitor [human]) for management of HEA; VP 20621 for the management of C.

ViroPharma Incorporated Key Recent Developments

Feb 27, 2013: ViroPharma Reports Revenue Of $427.9m In 2012
Oct 25, 2012: ViroPharma Reports Revenue Of $91m In Q3 2012
Sep 10, 2012: ViroPharma To Expand Pennsylvania Operations
Aug 09, 2012: ViroPharma Reports Revenue Of $94.6m In Q2 2012
May 29, 2012: Briscoe Law Firm And Powers Taylor Announce Investigation Into ViroPharma Incorporated

This comprehensive SWOT profile of ViroPharma Incorporated provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. SHOW LESS READ MORE >

List of Tables
List of Figures
Section 1 - About the Company
ViroPharma Incorporated - Key Facts
ViroPharma Incorporated - Key Employees
ViroPharma Incorporated - Key Employee Biographies
ViroPharma Incorporated - Major Products and Services
ViroPharma Incorporated - Pharmaceutical Pipeline Products Data
ViroPharma Incorporated, Pipeline Products by Therapy Area
ViroPharma Incorporated, Pipeline Products by Development Phase
ViroPharma Incorporated - History
ViroPharma Incorporated - Company Statement
ViroPharma Incorporated - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
ViroPharma Incorporated - Business Description
ViroPharma Incorporated - Corporate Strategy
ViroPharma Incorporated - SWOT Analysis
SWOT Analysis - Overview
ViroPharma Incorporated - Strengths
Strength - Innovative Product Portfolio
Strength - Emphasis on Research
Strength - Business Alliances
ViroPharma Incorporated - Weaknesses
Weakness - Failures of Clinical Trials
Weakness - Declining Revenues of Vancocin
ViroPharma Incorporated - Opportunities
Opportunity - Strategic Business Initiatives
Opportunity - Emerging Markets
Opportunity - Biotech Focus
ViroPharma Incorporated - Threats
Threat - Risk of Biological Contamination
Threat - Intense Competition
Threat - Stringent Government Regulations
ViroPharma Incorporated - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
ViroPharma Incorporated, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
ViroPharma Incorporated, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
ViroPharma Incorporated, Recent Deals Summary
Section 5 – Company’s Recent Developments
ViroPharma Incorporated, Recent Developments
Feb 27, 2013: ViroPharma Reports Revenue Of $427.9m In 2012
Oct 25, 2012: ViroPharma Reports Revenue Of $91m In Q3 2012
Sep 10, 2012: ViroPharma To Expand Pennsylvania Operations
Aug 09, 2012: ViroPharma Reports Revenue Of $94.6m In Q2 2012
May 29, 2012: Briscoe Law Firm And Powers Taylor Announce Investigation Into ViroPharma Incorporated
May 01, 2012: ViroPharma Reports Net Product Sales Of $135.8m In Q1 2012
Feb 28, 2012: ViroPharma Reports Net Product Sales Of $145.6m In Q4 2011
Jan 03, 2012: ViroPharma Appoints Julie McHugh To Board
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
ViroPharma Incorporated, Key Facts
ViroPharma Incorporated, Key Employees
ViroPharma Incorporated, Key Employee Biographies
ViroPharma Incorporated, Major Products and Services
ViroPharma Incorporated, Number of Pipeline Products by Therapy Area
ViroPharma Incorporated, Number of Pipeline Products by Development Stage
ViroPharma Incorporated, Pipeline Products By Therapy Area and Development Phase
ViroPharma Incorporated, History
ViroPharma Incorporated, Subsidiaries
ViroPharma Incorporated, Key Competitors
ViroPharma Incorporated, Ratios based on current share price
ViroPharma Incorporated, Annual Ratios
ViroPharma Incorporated, Interim Ratios
ViroPharma Incorporated, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
ViroPharma Incorporated, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
ViroPharma Incorporated, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
ViroPharma Incorporated, Pipeline Products by Therapy Area
ViroPharma Incorporated, Pipeline Products by Development Phase
ViroPharma Incorporated, Performance Chart (2008 - 2012)
ViroPharma Incorporated, Ratio Charts
ViroPharma Incorporated, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
ViroPharma Incorporated, Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013

Sanofi
Gilead Sciences, Inc.
Dyax Corp.
Optimer Pharmaceuticals, Inc.
Cubist Pharmaceuticals, Inc.